Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC to issue new guidelines for COVID-19 vaccinated patients

The Centers for Disease Control and Prevention is finalizing guidance aimed at clarifying what Americans who have received COVID-19 vaccines should and shouldn’t do, according to two sources at the agency familiar with its drafting.

The upcoming guidance, first reported by Politico, is expected to include that fully vaccinated individuals should be able to gather in small groups with other people who have also been vaccinated. The CDC currently does not recommend in-person gatherings with the general public, saying “gathering virtually or with the people you live with is the safest choice.”

Even for people who have been fully vaccinated, other mitigation measures will still be recommended, including wearing a mask in public and social distancing.

Source: CBS

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!